Robatumumab

Synonyms: 罗妥木单抗; Sch 717454; 19D12
Robatumumab (Sch 717454) 是一种抗人 IGF-1R(胰岛素样生长因子 1 受体)抗体,具有抗肿瘤和抗癌细胞增殖活性,可用于骨肉瘤和尤文肉瘤的研究。
产品编号: MS-B74005 纯度: 98.00% CAS No.: 934235-44-6
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Robatumumab (Sch 717454) 是一种抗人 IGF-1R(胰岛素样生长因子 1 受体)抗体,具有抗肿瘤和抗癌细胞增殖活性,可用于骨肉瘤和尤文肉瘤的研究。

生物实验数据

生物活性 Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor 1 receptor) antibody that exhibits antitumor and anti-cancer cell proliferation activities and can be used for research on osteosarcoma and Ewing sarcoma.
IC50 & Target

IGF1R/CD221

体外研究
(In Vitro)

Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells.

Western Blot Analysis

Cell Line: SK-N-FI cells
Concentration: 0.02-80 nM
Incubation Time: 0.5 or 4 hours
Result: Inhibited the IGF-I–stimulated phosphorylation of IGF-IR after treatment 0.5 h.
Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h.
Resulted in a dose-dependent inhibition of the IGF-I–stimulated IRS-1 phosphorylation.
体内研究
(In Vivo)

Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model.
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model.
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model.
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo.
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect.

Animal Model: Nude mice inoculated with SK-N-FI tumor cells
Dosage: 0.04 or 0.1 mg/mouse
Administration: Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days
Result: Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group.
Animal Model: Nude mice inoculated with SJSA-1 osteosarcoma
Dosage: 0.02, 0.1 or 0.5 mg/mouse
Administration: Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days
Result: Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment.
Animal Model: Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells
Dosage: 0.1 or 0.5 mg/mouse
Administration: Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days
Result: Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model.
Animal Model: Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma
Dosage: 0.1 or 0.5 mg/mouse
Administration: Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks
Result: Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft.
Animal Model: Nude mice inoculated with SJSA-1 osteosarcoma
Dosage: 0.5 mg/mouse
Administration: Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation
Result: Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT00551213Merck Sharp & Dohme LLC
Colorectal Cancer
2007-11-21PHASE2
NCT00954512Merck Sharp & Dohme LLC
Neoplasms
2009-09-25PHASE1|PHASE2
NCT00617890Merck Sharp & Dohme LLC
Osteosarcoma|Sarcoma, Ewing´s|Peripheral Neuroectodermal Tumor
2008-02-01PHASE2
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 934235-44-6
别名 罗妥木单抗; Sch 717454; 19D12

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础